StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) company profile

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.85−0.38 (-11.61%)

Close on Nov 17, 2026Market cap $234.24MP/E –Yield –

About Lexeo Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Lexeo Therapeutics is a clinical-stage genetic medicine company that develops gene therapies for cardiovascular diseases with underlying genetic causes. Its therapeutic pipeline includes LX2006, an adeno-associated virus gene therapy candidate that delivers a functional frataxin gene to treat Friedreich ataxia cardiomyopathy. Another primary candidate, LX2020, delivers a functional PKP2 gene to address arrhythmogenic cardiomyopathy caused by PKP2 mutations. The company also develops LX2021 to provide functional connexin 43 protein for inherited cardiac muscle disorders. Operating within the biotechnology and genetic medicine sector, the company focuses on serving patients suffering from serious hereditary heart conditions.

The company is headquartered in New York, New York, where it maintains principal executive offices. Its clinical-stage research and development activities operate primarily in the United States, where its product candidates undergo evaluation in clinical trials. Lexeo maintains exclusive worldwide development and commercialization rights across all of its therapeutic programs, which target patient populations in the United States and international markets.

Summary of the business section of Lexeo Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Lexeo Therapeutics, Inc.
Headquarters
New York, NY
Address
345 Park Avenue South, Floor 6 10010
Phone
(212) 547-9879
Employees
59, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Auditor
KPMG LLP, New York, NY

Stock & identifiers

Ticker
LXEO
Exchange
Nasdaq
IPO date
Nov 6, 2023
Shares outstanding
82M, Aug 10, 2026
Public float
$216.50M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1907108
CUSIP
52886X107
ISIN
US52886X1072
FIGI
BBG00YB1C8M5
Share class FIGI
BBG00YB1C8N4
EIN
85-4012572

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Richard Nolan TownsendChief Executive Officer, Director376,778
Narinder Pal BhallaChief Medical Officer84,908
Jose Manuel OteroChief Operating Officer138,288
Louis Edward TamayoChief Financial Officer92,907
Eric AdlerChief Medical Officer72,646
Jenny RobertsonChief Legal Officer68,381
Tai Sandi SeeChief Development Officer65,476
Kyle RasbachChief Financial Officer40,875
Tobin SchilkeDirector–
Brenda CooperstoneDirector–
Tolga TangulerDirector–
Mette Kirstine AggerDirector–
Reinaldo M. DiazDirector–
Paula H. CholmondeleyDirector30,627
Hauwermeiren Timothy VanDirector–
Steven AltschulerDirector–
Laura Sepp-LorenzinoDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
R. Nolan Townsend
Chief Executive Officer and Director
$632.70K$1.49M$1.17M$347.99K$10.79K$3.65M-17%
Louis Tamayo
Chief Financial Officer
$181.82K$215.55K$1.07M$197.76K$4.77K$1.67M–
Jenny R. Robertson
Former Chief Legal Officer
$459.60K$485.61K$407.44K$183.84K$609.39K$2.15M-14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 6, 2023
Offer price
$11.00
Securities offered
9,090,910
Gross proceeds
$100.00M
Exchange
Nasdaq
First trading day
Nov 3, 2023
First-day close
$10.05-8.6%
Lock-up ends (est.)
May 1, 2024

“The initial public offering price is $11.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 59 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?